A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region
Latest Information Update: 28 Sep 2020
At a glance
- Drugs TDENV LAV (Primary) ; TDENV PIV (Primary)
- Indications Dengue
- Focus Adverse reactions; First in man
- 23 Sep 2020 Results published in the Journal of Infectious Diseases
- 02 May 2017 Status changed from recruiting to completed.
- 31 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.